东曜药业

TOT Biopharm, founded in 2010 as the TTY's oncology business unit, is a public biotechnology company focused on developing and commercializing therapies for the potential treatment of cancer.By December 2019, the company established an antibody drug production base with a designed production capacity of 16,000L, forming a comprehensive and high-quality drug and product chain.In May 2011, the company held a first-stage construction foundation stone laying ceremony in Suzhou Industrial Park, China. In June 2012, the company planned to launch the construction of Biopharm Suzhou Factory with the first production of anticancer drugs planned for 2012. At that time, the company also intended to launch the second-stage extensive construction within three years; in December 2012, TOT Biopharm completed the 18-month project constructing the first stage of its US$ 100 million factory complex in eastern China's Suzhou Industrial Park which included an oral anti-cancer drug plant with separate prod